BioCentury | Jun 13, 2020
Translation in Brief

OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more

mAbs against new myeloid checkpoint OSE Immunotherapeutics S.A. (Euronext:OSE) has identified CLEC1A, a carbohydrate-binding protein, as a tumor myeloid checkpoint target, and has generated mAbs that prevent CLEC1A from binding its ligand on tumor cells....
BioCentury | May 28, 2020
Distillery Therapeutics

Epigenetic enzyme Tet1 as osteoarthritis target

...osteoarthritis. In patient-derived chondrocytes, an shRNA against Tet1 reduced mRNA levels of two disease markers, MMP3...
...inhibitor tool compound decreased cartilage loss and MMP13 secretion. TARGET/MARKER/PATHWAY: Tet methylcytosine dioxygenase 1 (Tet1); matrix metalloproteinase 3 (MMP3)...
BioCentury | Apr 11, 2020
Product Development

COVID-19 roundup: Lilly joins NIH’s adaptive trial; plus Foresee, Congress, ASCO, BMS, Otsuka, EC, Terumo-Marker

Eli Lilly’s rheumatoid arthritis drug Olumiant baricitinib has become the second treatment added to NIH’s COVID-19 master protocol, joining Gilead’s remdesivir. Separately, U.S. representatives called on FDA to ensure diagnostics are accurate, and ASCO launched...
BioCentury | Mar 7, 2020
Translation in Brief

Repurposing a protease inhibitor for COVID-19; plus City of Hope’s scorpion venom CAR T and Blaze’s tech for tissue-targeted steroid delivery

Protease inhibitor blocks COVID-19 viral fusion Camostat mesylate, a TMPRSS2 inhibitor already approved in Japan for digestive system indications, has become one of the latest drugs that could be repurposed to treat COVID-19. A team...
BioCentury | Jan 9, 2020
Targets & Mechanisms

Cancer's trajectory, as viewed by targets at AACR, ASCO and ASH

Beyond the headliner presentations at 2019’s three major cancer conferences were over a hundred posters and presentations showcasing new or emerging targets. A look at the identity of those targets reveals the growing diversity of...
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Jul 10, 2019
Distillery Therapeutics

Reducing adipogenesis by fibroadipogenic precursors could treat limb-girdle muscular dystrophy

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy Inhibiting ANXA2 or MMP could treat limb-girdle muscular dystrophy (LGMD2B) by preventing fibroadipogenic precursor cells from accumulating and undergoing adipogenesis. In three patients with LGMD2B, which is caused by...
BioCentury | May 23, 2019
Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

A pair of newly listed biotechs trended in opposite directions during first-day trading Thursday. Bicycle slipped 14% after pricing its IPO at the bottom end of its proposed range, while Ideaya was up 12% after...
BioCentury | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
Items per page:
1 - 10 of 513